Angelini Labopharm Aug. 10 announced that Oleptro (trazodone hydrochloride extended-release tablets), a novel once-daily formulation of the antidepressant trazodone, is now commercially available in the United States.
Oleptro was approved by the Food and Drug Administration in February (8 PLIR 191, 2/12/10).
Canadian company Labopharm Inc. and Italy-based Angelini established Angelini Labopharm in May for the purpose of commercializing Oleptro in the United States. Angelini Labopharm is equally owned by both companies.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.